Kinetic and affinity constants of epitope specific anti-carcinoembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain constructs

被引:41
作者
Hefta, LJF
Neumaier, M
Shively, JE
机构
[1] City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA
[2] Univ Hamburg, Klin Chem Abt, Hamburg, Germany
来源
IMMUNOTECHNOLOGY | 1998年 / 4卷 / 01期
关键词
carcinoembryonic antigen; monoclonal antibody; BIAcore;
D O I
10.1016/S1380-2933(98)00004-9
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Carcinoembryonic antigen (CEA) is a human tumor antigen with the domain structureN-A1-B1-A2-B2-A3-B3, in which each domain is predicted to have an Ig- like fold and is known to bind epitope specific anti-CEA antibodies. Objective: To determine the affinity constants of several domain specific anti-CEA antibodies using purified recombinant or synthetic domains. Results and Conclusions: We have determined the kinetic and affinity constants of several anti-CEA antibodies for CEA, CEA domains (A3-B3) expressed in HeLa cells, and a synthetic peptide corresponding to the A3 domain using a BIAcore biosensor. There was no difference in affinity for CEA among a murine (mT84.66), a mouse/human chimeric form (cT84.66) or a disulfide deleted version (Delta SScT84.66) of this antibody. There was less than a five-fold drop in affinity of murine T84.66 for the A3-B3 domain expressed in HeLa cells compared to CEA. The synthetic A3 domain had an affinity constant for mT84.66 which was ten-fold less than for CEA. The affinity constants for CEA with several other anti-CEA monoclonal antibodies, including three antibodies which have almost identical CDR sequences (CEA.281, CEA.11 and CEA.231) were also determined. CEM231 which had a two-fold higher affinity constant for CEA than either CEA.281 or CEA.11 had a two-fold faster on-rate which accounts for its higher affinity constant. This difference may be due to one or more of the amino acid differences present in H1 (N vs. S or D) and H3 (A vs. V). (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:49 / 57
页数:9
相关论文
共 17 条
[1]  
BEIDLER CB, 1988, J IMMUNOL, V141, P4053
[2]  
CONRY RM, 1995, GENE THER, V2, P59
[3]   IMMUNE-RESPONSE TO THE CARCINOEMBRYONIC ANTIGEN IN PATIENTS TREATED WITH AN ANTIIDIOTYPE ANTIBODY VACCINE [J].
FOON, KA ;
CHAKRABORTY, M ;
JOHN, WJ ;
SHERRATT, A ;
KOHLER, H ;
BHATTACHARYACHATTERJEE, M .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (01) :334-342
[4]  
GAIDA FJ, 1993, J BIOL CHEM, V268, P14138
[5]  
HAMMARSTROM S, 1989, CANCER RES, V49, P4852
[6]  
HASS GM, 1991, CANCER RES, V51, P1876
[7]  
HEFTA LJ, 1996, ANTIBODY ENG PRACTIC, P99
[8]  
HEFTA LJF, 1992, CANCER RES, V52, P5647
[9]  
McLaughlin JP, 1996, CANCER RES, V56, P2361
[10]  
NEUMAIER M, 1990, CANCER RES, V50, P2128